ClinicalTrials.gg
TerminatedNCT01038752Updated May 21, 2015Results posted

Evaluation of Non-cytotoxic Suramin as a Chemosensitizer in Non-small Cell Lung Cancer

A Phase 2 interventional study of Suramin Drug:Docetaxel Drug: Carboplatin and Placebo Drug: Docetaxel Drug: Carboplatin in Non-small Cell Lung Cancer, sponsored by Optimum Therapeutics, LLC. Terminated at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-05-21.

Sponsored by Optimum Therapeutics, LLC · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
14
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 271 studies testing carboplatin in Carcinoma, Non-Small-Cell Lung — 21 open to participants now, 39 under way, 11 of them phase 3. Carboplatin · Carcinoma, Non-Small-Cell Lung.

Enrollment
211th of 250
14 · median 55
Started
2010
with 7 others
Phase 2
149 of 271
11 open now
Registered
149th of 271
by date

Among the 271 studies testing carboplatin in Carcinoma, Non-Small-Cell Lung, this one is the 211th largest by enrollment of the 250 interventional ones that give a count, is one of 8 that started in 2010, is one of 149 in phase 2, and was the 149th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

21 of the 271 studies testing carboplatin in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 21 open studies →

About carboplatin

Carboplatin: first FDA approval 1989 (PARAPLATIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 271 studies testing carboplatin in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the benefit of adding suramin at a non-cytotoxic dose to carboplatin and docetaxel regimen in the treatment of chemo-naïve patients with non-small cell lung cancer.

Read the detailed description

The primary objective is to determine the progression free survival for patients with stage III B with malignant pleural effusion or Stage IV NSCLC treated with docetaxel and carboplatin with or without suramin.

The secondary objectives are to compare median overall survival rate, compare overall response rate of patients in both arms, assess toxicity of suramin with docetaxel and carboplatin, determine whether pre-treatment bFGF levels correlate with survival, to determine whether survival benefit from suramin is associated with M phase entry in peripheral blood lymphocytes, and to determine whether adding suramin to docetaxel and carboplatin produces greater survival benefits in African-American patients.

03

Conditions studied

  • Non-small Cell Lung Cancer

Keywords

  • NSCLC
  • suramin
  • lung cancer
  • chemotherapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically proven on-small cell lung cancer (NSCLC), including squamous cell carcinoma.
  • Newly-diagnosed stage IIIB with malignant pleural effusion, stage IV or recurrent disease.
  • Known central nervous system if patients are asymptomatic and have completed whole brain or stereotactic radiation at least 2 weeks prior or surgery at least 4 weeks prior to starting treatment on this protocol. Must be off dexamethasone at the time of starting treatment.
  • Must have completed radiotherapy at least two weeks prior to registration. Prior radiation therapy is eligible if patient has a that has not been irradiated.
  • Must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension ( criteria).
  • Lesions that are not considered measurable include the following:

    • Bone lesions
    • Ascites
    • Pleural/pericardial effusion
    • Abdominal masses that are not confirmed and followed by imaging techniques
    • Cystic lesions
    • Tumor lesions situated in a previously irradiated area
  • performance status of 0-1.
  • ≥ 3 months.
  • Adequate bone marrow function, ≥1,500/mm3, ≥9.9 gm/dl, and count ≥100,000/mm3.
  • Adequate liver function defined as ≤ 1x upper level of the institutional normal (ULIN). and ALT and Alkaline Phosphatase must be within the range allowing for eligibility. In determining eligibility the more abnormal of the two values (AST or ALT) should be used. See protocol.
  • Must have adequate renal function defined as serum creatinine ≤ 2.0 mg/dl or calculated ≥ 60 ml/min for patients with creatinine levels above 2.0 mg/dl.
  • Must have recovered from uncontrolled intercurrent illness, including ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris or cardiac arrhythmia.
  • Use of adequate (hormonal or barrier method of birth control) for the duration of study participation and continued for at least three months after completing treatment. Non-pregnant status will be determined in all women of .
  • Age > 18.
  • Patients must have given written .
  • Entry to this study is open to both men and women and to all racial and ethnic subgroups. The goal is to accrue a minimum of 44 patients of African-American ancestry and a maximum of 120 non-African-American patients. Classification of patient race and ancestry will be based on patient's self-identification on the consent form for the clinical trial.

Exclusion criteria

Exclusion Criteria:

  • History of severe reaction to Docetaxel or other drugs formulated with polysorbate 80.
  • Grade 3 or 4 neuropathy.
  • Women who are pregnant or breast-feeding.
  • Prior chemotherapy or biologic therapy (e.g., erlotinib) for NSCLC including or adjuvant chemotherapy.
  • Currently active second other than non-melanoma skin cancer. Currently active malignancy does not include prior malignancy treated with therapy and considered to have less than 30% risk of relapse.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    Suramin

    This group will receive the combination of non-cytotoxic suramin with docetaxel and carboplatin.

    Drug: Suramin Drug:Docetaxel Drug: Carboplatin

  • Placebo comparator
    Standard of care

    This group will receive placebo with docetaxel and carboplatin.

    Drug: Placebo Drug: Docetaxel Drug: Carboplatin

Interventions

  • Suramin dosage will be determined by nomogram and administered over 30 minutes. Suramin is followed by docetaxel (56 mg/m2, administered over 1 hour), followed by carboplatin (dosage calculated by Calvert equation to have a target AUC of 6, administered over 1 hour).

    Also known as: CI-1003, PD 002927-0015F, NSC 34936, Bayer 205, Germanin, Metaret, Taxotere, Paraplatin

  • DrugPlacebo Drug: Docetaxel Drug: Carboplatin

    Placebo (100 ml of 0.9% sodium chloride or 5% dextrose in water) will be administered over 30 minutes, followed by docetaxel (75 mg/m2, administered over 1 hour), followed by carboplatin (dose calculated by Calvert equation to have a target AUC of 6, administered over 1 hour).

    Also known as: Taxotere, Paraplatin

06

What researchers measure

Primary outcomes

  1. Progression-free Survival for Participants With Stage IIIB/IV NSCLC Per RECIST Criteria

    Insufficient data

    Time frame: Patients will be followed every 2 months for the first 6 months following the last cycle of treatment, every three months for the next year, and every 6 months thereafter.

Secondary outcomes

  1. Overall Survival of Participants

    Insufficient Data

    Time frame: First treatment date to date of death

  2. Overall Response Rate (Complete Response + Partial Response) of Participants

    Insufficient data

    Time frame: Tumor assessment at every other cycle

  3. Toxicity of Combination of Non-cytotoxic Suramin With Docetaxel and Carboplatin.

    Insufficient data.

    Time frame: Day 1 of each cycle; end of treatment visit; at follow-up.

  4. Pre-treatment bFGF Levels Correlation With Survival.

    Insufficient data.

    Time frame: Before first treatment

  5. Survival Benefit From Non-cytotoxic Suramin Association With Reduced M-phase Entry in Peripheral Blood Lymphocytes

    Insufficient data.

    Time frame: Randomization date

  6. To Determine Whether Adding Non-cytotoxic Suramin to Docetaxel and Carboplatin Produces Survival Benefits in African-American Patients.

    Insufficient data.

    Time frame: Randomization date to date of death

  7. To Determine Whether Adding Non-cytotoxic Suramin to Docetaxel and Carboplatin Produces Greater Survival Benefits in African-American Patients Compared to Non-African-American Patients.

    Insufficient data.

    Time frame: Randomization date to date of death

07

Results

Posted Oct 21, 2014
Limitations and caveats
The study was terminated prematurely due to the loss of follow-up of 6 of 14 participants before progression and slow accrual. Due to the resulting small numbers, no analysis was attempted.

Participant flow

A total of 164 subjects were expected to be enrolled in this study; however, only a total of 14 subjects were enrolled at two active sites. Site 001 (Virginia Commonwealth University) enrolled 4 subjects and site 002 (Cook County) enrolled 10 subjects for a total of 14 subjects.

Participant flow — Overall Study
MilestoneSuraminStandard of Care
Started86
Completed31
Not completed55
Withdrew: Tumor progression22
Withdrew: Lost to follow-up33

Outcome measures

PrimaryProgression-free Survival for Participants With Stage IIIB/IV NSCLC Per RECIST Criteria

Insufficient data

Time frame:
Patients will be followed every 2 months for the first 6 months following the last cycle of treatment, every three months for the next year, and every 6 months thereafter.

No measurements were reported for this outcome.

SecondaryOverall Survival of Participants

Insufficient Data

Time frame:
First treatment date to date of death

No measurements were reported for this outcome.

SecondaryOverall Response Rate (Complete Response + Partial Response) of Participants

Insufficient data

Time frame:
Tumor assessment at every other cycle

No measurements were reported for this outcome.

SecondaryToxicity of Combination of Non-cytotoxic Suramin With Docetaxel and Carboplatin.

Insufficient data.

Time frame:
Day 1 of each cycle; end of treatment visit; at follow-up.

No measurements were reported for this outcome.

SecondaryPre-treatment bFGF Levels Correlation With Survival.

Insufficient data.

Time frame:
Before first treatment

No measurements were reported for this outcome.

SecondarySurvival Benefit From Non-cytotoxic Suramin Association With Reduced M-phase Entry in Peripheral Blood Lymphocytes

Insufficient data.

Time frame:
Randomization date

No measurements were reported for this outcome.

SecondaryTo Determine Whether Adding Non-cytotoxic Suramin to Docetaxel and Carboplatin Produces Survival Benefits in African-American Patients.

Insufficient data.

Time frame:
Randomization date to date of death

No measurements were reported for this outcome.

SecondaryTo Determine Whether Adding Non-cytotoxic Suramin to Docetaxel and Carboplatin Produces Greater Survival Benefits in African-American Patients Compared to Non-African-American Patients.

Insufficient data.

Time frame:
Randomization date to date of death

No measurements were reported for this outcome.

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Suramin—3/8 (37.5%)6/8 (75%)
Standard of Care—0/6 (0%)6/6 (100%)
Most frequent serious events
Most frequent serious events
EventSuraminStandard of Care
Pericardial EffusionCardiac disorders1/80/6
Acute Renal FailureRenal and urinary disorders1/80/6
HematuriaRenal and urinary disorders1/80/6
Altered mental statusPsychiatric disorders1/80/6
DyspneaRespiratory, thoracic and mediastinal disorders1/80/6
Most frequent other events
Showing 10 of 23
Most frequent other events
EventSuraminStandard of Care
AnemiaBlood and lymphatic system disorders5/86/6
Fatigue/astheniaGeneral disorders5/85/6
NauseaGeneral disorders5/81/6
AnorexiaMetabolism and nutrition disorders5/80/6
LeukopeniaBlood and lymphatic system disorders3/82/6
ThrombosisVascular disorders3/80/6
VomitingGeneral disorders3/80/6
ConstipationGeneral disorders3/80/6
Mayalgias/ArthralgiasMusculoskeletal and connective tissue disorders1/82/6
Fluid Retention/EdemaGeneral disorders1/82/6

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)SuraminStandard of CareTotal
<=18 years000
Between 18 and 65 years527
>=65 years347
Sex: Female, Male
Sex: Female, Male(Participants)SuraminStandard of CareTotal
Female257
Male617
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)SuraminStandard of CareTotal
Hispanic or Latino000
Not Hispanic or Latino8614
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)SuraminStandard of CareTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American5510
White314
More than one race000
Unknown or Not Reported000
Non-small cell lung cancer (NSCLC) Disease Stage at Entry
Non-small cell lung cancer (NSCLC) Disease Stage at Entry(participants)SuraminStandard of CareTotal
IIIB101
IV7613
Non-small cell lung cancer (NSCLC) Disease Type
Non-small cell lung cancer (NSCLC) Disease Type(participants)SuraminStandard of CareTotal
Squamous224
Nonsquamous6410
08

Study locations

2 sites
  • John H Stroger Jr Hospital of Cook County
    Chicago, Illinois 60612, United States
  • Virginia Commonwealth University Massey Cancer Center
    Richmond, Virginia 23298, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2010, a primary completion of Nov 2012 and a completion of May 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2014, 1 year 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2009
First posted
Dec 24, 2009
Start
Aug 2010
Primary completionActual
Nov 2012
CompletionActual
May 2013
Results first posted
Oct 21, 2014
Last update
May 21, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 21, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01038752
Lead sponsor
Optimum Therapeutics, LLC
Responsible party
Sponsor
First posted
Dec 24, 2009
Start date
Aug 2010
Primary completion
Nov 2012
Completion
May 2013
Results posted
Oct 21, 2014
Last update
May 21, 2015

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Carboplatin

Start the discussion